Akeso Fell While Sales Rose

If you had backed Akeso for its bispecific pipeline and China focus, the past year has been uncomfortable. For Akeso shareholders, the loss over the past year was 25.5%, including dividends. That sits awkwardly against the earlier October 2025 projections that relied on three years of rapid revenue expansion, a sharp swing from losses to strong margins, and high future P/E multiples. If the thesis hinged on cadonilimab and ivonescimab broadening access, which of those specific assumptions broke first?

A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.

Akeso has already moved. Pinpoint other ways to investigate the theme among 127 healthcare AI stocks.

The Two Akeso Stories Investors Were Really Weighing

The shares cost HK$128 at the start of the period, and Akeso sat between two very different stories that both sounded reasonable on the facts available then.

The bullish narrative saw fair value at HK$169, 33% above the start price, built on assumptions of 59.0% revenue growth and a 40.8% profit margin within three years as cadonilimab and ivonescimab expanded access through NRDL inclusion and wider Phase III use.

The bearish case pointed to fair value of HK$88.38, 31% below the start price, arguing that deep 53% to 54% price cuts in China could compress margins and leave Akeso exposed to heavy competition and pipeline concentration risk.

What The Evidence Around Akeso Actually Tested

Ivonescimab cleared a major hurdle as China approved it with chemotherapy for first line advanced squamous NSCLC, and several Phase III trials in lung and biliary cancers reported significant survival benefits, which supported the bullish focus on clinical breadth and access. At the same time, Akeso still reported a net loss in H1 2026, so the earlier high margin targets remained unproven. Overall, the evidence cut both ways.

The key assumption here was not just trial success, but how quickly that translated into profitable earnings. When you look at another biotech, check whether rising sales and better reported net margin are actually closing the gap from losses to the level of profitability the original thesis relied on.

What Akeso’s Drop Leaves You Weighing Today

Akeso now trades at HK$91.3, with the selected Narrative arguing that its Fair Value sits above that level based on a broader multi franchise oncology and immunology story.

The Narrative focuses on continued progress for ivonescimab, cadonilimab, ADC programs and gumokimab. To see the fall as a potential opportunity rather than a warning, an investor would need to be confident that these emerging franchises can develop into a more diversified earnings base.

"The current valuation suggests that Akeso’s share price does not fully reflect the potential contribution from its growing bispecific, ADC, and hematology pipelines, as well as the early commercial ramp of products like ivonescimab and gumokimab."

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for

Which Company Could Surprise You Next?

The next headline does not have to be where your research begins. Go straight to the companies and see whether a contrarian opportunity could be taking shape.

• Company 1 - 29% below our estimate - shifts its loan book toward secured borrowers in infrastructure and energy projects.
• Company 2 - 40% below our estimate - adds automated aerostructure capacity to capture demand for aircraft and drone components.
• Company 3 - 34% below our estimate - converts AI infrastructure and multicloud database contracts into subscription-based software and cloud revenue.

Three companies from the same screener. Open all 191 potentially undervalued companies →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com